23rd week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160158114 | Disposable Emesis Bag with Comfort Features - A disposable emesis bag comprising a soft cushioning material at the opening of the bag to improve the user's comfort while and after vomiting. The soft cushioning material can be attached only to the portions of the bag that come into contact with the user's nose or chin, or around the entire perimeter of the opening of the bag. The bag may be scented or odor-absorbing, and is preferably waterproof. | 2016-06-09 |
20160158115 | Color Cosmetic with High Coverage and Naturalness - Described herein is a cosmetic composition comprising a mixture of metal oxide pigments having different shapes and sizes which provides high coverage and a natural look upon application. | 2016-06-09 |
20160158116 | WRINKLE REDUCING SKIN PATCH, PROCESS OF MANUFACTURE AND USEFUL ARTICLES THEREOF - This invention relates to a novel method of reducing the appearance of rhytides (“facial wrinkles”) and/or infra-orbital shadows (“dark circles”) under the eyes, and striae (“stretch marks”), or lentigo senilis (“age spots”), and hyper/hypo pigmentation on other anatomical areas. Particularly, this invention relates to a topical patch worn on the skin that in a preferred embodiment incorporates two distinct layers, each providing useful features and together providing a novel article and method of improving skin cosmesis. Ease of use, patient comfort and cost effectiveness are provided. The patch is applied to the affected area and preferably worn at least several hours and more preferably worn overnight. The product increases the hydration level of the skin over which it is applied. There is a slight increase to the volume of the local superficial tissue, which serves to tighten the overlying skin and reduce the size and quantity of fine wrinkles at least temporarily. Various active ingredients, such as peptides, vitamin compounds, antioxidants, growth factors, glycolic or alphahydroxy acids, etc., may be incorporated into the present invention thereby providing an enhanced effect or other perceived advantage in the market. | 2016-06-09 |
20160158117 | LONG LASTING BREATH MINT - A long lasting breath mint including a carrier and a flavorant, wherein the carrier includes at least one of a high viscosity cellulose ether and a low viscosity cellulose either and an alginate. The carrier forms a gel upon contact with saliva. A tablet is placed in the mouth of user, whereupon the tablet is wetted with saliva. A surface of the tablet is converted to a gel resulting in a tablet having an outer gel layer and a core. The gel serves as an adhesive for adhering the tablet to mouth structure. The gel slows exposure of the core to moisture and also slows diffusion of flavorant into the mouth of the user with the gel resulting in a breath mint having an extremely long life prior to complete dissolution, e.g., greater than 30 minutes or longer. | 2016-06-09 |
20160158118 | OIL/OIL EMULSIONS CONTAINING PARTICLES WITH A BREAKAGE OF CURVATURE, COMPOSITIONS COMPRISING THEM AND USE OF THE PARTICLES FOR STABILIZING O/O EMULSIONS - The present invention relates to an oil/oil emulsion comprising at least: —a first oily phase comprising at least a first non-volatile oil chosen from silicone oils, hydrocarbon-based oils and fluoro oils, —a second oily phase comprising at least a second volatile or non-volatile oil, which is immiscible with the first oil(s) at room temperature, —solid microparticles having at least one curved part and at least one breakage of curvature of the said curved part. The invention also relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one such oil/oil emulsion. Finally, the invention relates to the use of solid microparticles having at least one curved part and at least one breakage of curvature of the said curved part, for stabilizing an oil/oil emulsion as has just been described. | 2016-06-09 |
20160158119 | PERSONALIZING SUBSTANCE FOR APPLICATION TO THE SKIN OR ADDITION TO TATTOO INK AND METHODS OF PREPARATION THEREOF - Compositions for delivering materials, such as a biological material, sand, soil, metal, water, sea water, holy water, synthetic or biological polymers, cremated ash, ceramics, animal or plant tissue, or another physiologically compatible component having personal significance to an individual are described herein. The material(s) are encapsulated in an inert, non-bioerodible, hydrophobic, polymeric material. Methods of making microparticles encapsulating the personalizing substance and methods of use are also provided. The personalizing substance may be encapsulated in a polymeric non-bioerodible microparticle. The encapsulated personalizing substance may be combined with a carrier for delivery to an individual's skin. In some embodiments, the personalizing substance is added to a tattoo ink and incorporated in a tattoo created on an individual's skin. Following injection in the skin, the encapsulated material remains in the microparticles, and is not released over time. | 2016-06-09 |
20160158120 | PERSONALIZING SUBSTANCE FOR APPLICATION TO THE SKIN OR ADDITION TO TATTOO INK AND METHODS OF PREPARATION THEREOF - Compositions for delivering materials, such as a biological material, sand, soil, metal, water, sea water, holy water, synthetic or biological polymers, cremated ash, ceramics, animal or plant tissue, or another physiologically compatible component having personal significance to an individual are described herein. The material(s) are encapsulated in an inert, non-bioerodible, hydrophobic, polymeric material. Methods of making microparticles encapsulating the personalizing substance and methods of use are also provided. The personalizing substance may be encapsulated in a polymeric non-bioerodible microparticle. The encapsulated personalizing substance may be combined with a carrier for delivery to an individual's skin. In some embodiments, the personalizing substance is added to a tattoo ink and incorporated in a tattoo created on an individual's skin. Following injection in the skin, the encapsulated material remains in the microparticles, and is not released over time. | 2016-06-09 |
20160158121 | POLYUREA CAPSULE COMPOSITIONS - A microcapsule composition useful in delivering an active material contains a first microcapsule and a second microcapsule. The first microcapsule has a zeta potential of 10 mV or greater, the second microcapsule has a zeta potential of 5 mV or less, and the weight ratio of the first microcapsule and the second microcapsule is between 1:10 and 10:1. Also disclosed are consumer products containing such a microcapsule composition. | 2016-06-09 |
20160158122 | Microbicidal Personal Care Compositions Comprising Metal Ions - Animate surface treatment compositions comprise (or in certain preferred embodiments may consist essentially of, or may consist of): a metal ion source material which releases copper ions and/or zinc ions into the treatment composition, in certain embodiments at least one alcohol which independently of other constituents present exhibits a microbicidal effect, in certain embodiments at least one quaternary ammonium compound which provides a microbicidal benefit, optionally but very preferably also at least one detersive surfactant, further optionally one or more further constituents which impart one or more advantageous technical or aesthetic benefits to the compositions, including one or more detersive surfactants, and water, wherein the compositions are at a pH such that the animate surface treatment compositions, exhibit a microbicidal or germicidal or antimicrobial effect on treated surfaces, which compositions are characterized in exhibiting a microbicidal benefit when tested against one or more challenge microorganisms according to one or more standardized test protocols. | 2016-06-09 |
20160158123 | KIT FOR WHITENING A BODY SURFACE OF A USER, RELATED METHOD AND PROCESS - Kit for whitening a body surface of a user, comprising:
| 2016-06-09 |
20160158124 | Beauty Care Product - A beauty care product comprising a sealable plastic container, a sealing means and a beauty care component is provided, wherein the container of which is resistant to random, uncontrolled deformation under a substantial pressure differential between the environment and inside the container, yet having an affordable cost of manufacture and/or being appealing to the consumer. A kit comprising said product thereof, a method of manufacturing said product, and a method of using said product for application onto skin and/or hair are also provided. | 2016-06-09 |
20160158125 | PRODUCTS FOR OXIDATIVELY CHANGING THE COLOR OF KERATIN FIBERS, IN A DISPENSER - A product for oxidatively coloring and/or lightening keratinic fibers includes (1) a dispenser, which has two chambers (A) and (B) separate from one another; an outlet opening (C) communicating with chamber (A) and with chamber (B); (2) a preparation (a) in chamber (A), which preparation includes one or more thickening polymers in a total amount by weight (G1) of 0.1 to 20%, based on preparation (a); one or more fatty components in a total amount by weight (G2) of 0.1 to 20%, based on preparation (a); and (3) a preparation (b) in chamber (B), which preparation includes one or more thickening polymers in a total amount by weight (G3) of 0.1 to 20%, based on preparation (b), and one or more fatty components in a total amount by weight (G4) of 0.1 to 20%, based on the total weight of the preparation (b). The weight ratio of G1/G3 has a value of 0.5 to 2.0 and the weight ratio of G2/G4 has a value of 0.5 to 2.0. | 2016-06-09 |
20160158126 | BLEACHING AGENT CONTAINING FATTY ALCOHOLS - Agents for lightening keratin fibers include, relative to their weight, 20 to 75 wt.-% oil(s), 0.05 to 5 wt.-% xanthan, 1 to 70 wt.-% peroxodisulfate(s) and 1 to 15 wt.-% cetearyl alcohol. The agents have increased storage stability, not only the physical stability (settling, phase separation) but also the chemical stability (degradation of the persalts) thereof being improved. | 2016-06-09 |
20160158127 | SKIN-CARE OIL - Cosmetic agents include liquid oils in a total amount of 80 to 99.5% by weight. The liquid oils include (a) at least one liquid oil with a spreadability value (25° C.) in a range of 100 mm | 2016-06-09 |
20160158128 | COMPOSITION FOR HAIR FRIZZ REDUCTION - The present invention is directed to a rinse-off conditioner composition for hair frizz reduction comprising from about 0.2% to about 20% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following: | 2016-06-09 |
20160158129 | PRODUCTS FOR OXIDATIVE COLOUR CHANGE OF KERATINOUS FIBRES IN A DISPENSER - A product for the coloring and/or lightening of keratinic fibers includes (1) a dispenser, having two chambers (A) and (B); (2) a preparation (a) in chamber (A), including in a cosmetic carrier one or more fatty components in a total amount by weight (G1) of 0.1 to 40% by weight, based on (a), one or more organic and/or inorganic salts in a total molality (M1) of 0.01 to 1 mol/kg, based on the total weight of (a); 3) a preparation (b) in chamber (B), including in a cosmetic carrier one or more fatty components in a total amount by weight (G2) of 0.1 to 40% by weight, based on (b), one or more organic and/or inorganic salts in a total molality (M2) of 0.01 to 1 mol/kg, based on (b), wherein the weight ratio G1/G2 has a value of 0.5 to 2.0 and the molality ratio M1/M2 has a value of 0.3 to 3.0. | 2016-06-09 |
20160158130 | HAIR DYE COMPOSITION - A hair dye composition is characterized by containing (A) HC BLUE No. 2, (B) DISPERSE VIOLET 1, and (C) at least one of HC YELLOW No. 2 and HC YELLOW No. 4 and has a pH of 7-11. The mass ratio of the content of (A) HC BLUE No. 2 to the content of (B) DISPERSE VIOLET 1 is preferably 1 to 30. The hair dye composition preferably further contains (D) DISPERSE BLACK 9. | 2016-06-09 |
20160158131 | Compositions and Methods for Stimulating Collagen Synthesis in the Skin - Cosmetic compositions comprising substituted carbamoyl heterocyclic analogs and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The substituted carbamoyl heterocyclic analogs are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging. | 2016-06-09 |
20160158132 | Stabilization of Cosmetic Compositions - Disclosed is the Use of UV absorbers selected from
| 2016-06-09 |
20160158133 | PRIMECOAT COMPOSITIONS FOR PROTEINACEOUS SUBSTRATES AND METHODS OF PRIMING PROTEINACEOUS SUBSTRATES THEREWITH - Compositions containing a solution of a polyfunctional aziridine component in a non-reactive solvent, and methods of applying such compositions to proteinaceous substrates, such as fingernails and toenails, to provide primed substrates which may be further coated. | 2016-06-09 |
20160158134 | Stable Vitamin C System - The present compositions include substantially anhydrous lotions, gels, or cremes having a high vitamin C content. The compositions described herein may be used as paste, lotions, cremes, or gels in and of themselves, or as a solvent/base system for additional ingredients. Additional ingredients may include therapeutically active ingredients, pigments, fragrances or other cosmetic additives. | 2016-06-09 |
20160158135 | COMPOSITION FOR HAIR FRIZZ REDUCTION - A composition directed to a rinse-off composition for hair frizz reduction comprising from about 0.2% to about 20.0% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following:
| 2016-06-09 |
20160158136 | COMPOSITION FOR REDUCTION OF TRPA1 AND TRPV1 SENSATIONS - A personal care composition and method of using a personal care composition having menthol and/or hydrogen peroxide and a TRPA1 and/or TRPV1 receptor antagonists. | 2016-06-09 |
20160158137 | HAIR TREATMENT SYSTEMS AND METHODS USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for transdermal delivery, and treatment of hair related conditions. The compositions can be used in a variety of applications, including causing or promoting hair growth and/or hair pigmentation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the scalp, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-06-09 |
20160158138 | KERATIN-BASED HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS - The present invention teaches a hair straightening system including formulations that will safely and effectively straighten curly hair for at least 2-3 months after a single application, despite frequent washings of the hair. Methods for obtaining said formulations are disclosed. Hair straightening systems including shampoo and one or more conditioners are also provided. | 2016-06-09 |
20160158139 | Compositions Comprising A Sirt6 Activator And A DNA Repair Enzyme - Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH | 2016-06-09 |
20160158140 | CROSS-LINKED HYALURONIC ACID, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN THE AESTHETIC FIELD - The present invention relates, in one aspect, to the use as dermal filler of a cross-linked biopolymer compatible with the tissues of the human organism based on hyaluronic acid cross-linked with urea. The biopolymer of hyaluronic acid and urea may be applied or injected in a soft tissue of human body for tissue augmentation. | 2016-06-09 |
20160158141 | FOAMING BLEACH-BLONDING COMPOSITIONS - Agents for lightening keratinic fibers, which include, based on their weight, 20 to 75% by weight of oil(s), 0.05 to 5% by weight of polymer(s) from the group of ethylene/propylene/styrene copolymers and/or butylene/ethylene/styrene copolymers and/or butylene/propylene/styrene copolymers, and 1 to 70% by weight of peroxydisulfate(s), whereby the weight ratio of sodium peroxydisulfate in the agent to the total amount of peroxydisulfates in the agent is at least 0.2, possess increased storage stability, the improvement being not only in physical stability (sedimentation, phase separation) but also in chemical stability (degradation of the persalts). There are also improvements in product yield, spreadability of the application mixture, and the bleaching effect. | 2016-06-09 |
20160158142 | BLEACHING AGENT CONTAINING POLYMERS - An agent for lightening keratin fibers, which, with regard to its weight, includes 20 to 75 wt. % of oil(s), 0.05 to 5 wt. % of polymer(s) from the group of copolymers of ethylene/propylene/styrene and/or copolymers of butylene/ethylene/styrene, and/or copolymers of butylene/propylene/styrene, and 1 to 70 wt. % of peroxydisulfate(s), wherein the fibres contain 1 to 44 wt. % of potassium peroxydisulfate and 0 to <5 wt. % of sodium peroxydisulfate, and 0 to <5 wt. % of ammonium peroxydisulfate. The agent has increased storage stability, whereby not only the physical stability (settling, phase separation) but also the chemical stability (decomposition of the peroxide salts) is improved. | 2016-06-09 |
20160158143 | COSMETIC COMPOSITIONS - Disclosed are compositions and methods for their use that include a combination of | 2016-06-09 |
20160158144 | COSMETIC COMPOSITIONS - Disclosed are compositions and methods that can be used to improve the skin's visual appearance. In certain aspects, the compositions disclosed herein can include, for example, a combination of ingredients to exfoliate, reduce or eliminate irritation from exfoliation, renew the skin, increase skin radiance, sooth the skin, or increase skin smoothness. This combination of ingredients can be included in a wide-range of product formulations (e.g., serums, eye creams, toners, gels, masks, peels, etc.). | 2016-06-09 |
20160158145 | Container - The present invention relates to a container for an analyte-sensitive gel. When analyte contacts such a gel it causes a gel-sol transition resulting in decreased viscosity of the gel. Such gels can be used for controlling the rate of release of an agent from a reservoir in response to the concentration of an analyte. The container is configured to allow analyte to pass into the container and contact the gel and to allow agent to diffuse out of the container. Such a container may be implantable in the body of a subject and therefore it is preferred if the container is constructed from materials that can be tolerated by the body for a period of time. Advantageously, the container limits the swelling and dilution of gel contained within the container caused by the influx of water into the gel by osmosis. The container therefore maintains the gel in a desired conformation and ensures a predictable release profile of the agent. | 2016-06-09 |
20160158146 | OCULAR THERAPEUTIC AGENT DELIVERY DEVICES AND METHODS FOR MAKING AND USING SUCH DEVICES - Ocular implant devices ( | 2016-06-09 |
20160158147 | COMPOSITION AND METHOD FOR ORALLY ADMINISTERING ONE OR MORE ACTIVE AGENTS TO A PET - A composition and method for administering an active agent to a pet, such as a dog, a cat or a horse. The composition may comprise a yogurt-based chewable delivery matrix and a plurality of water-soluble film pieces dispersed throughout the chewable delivery matrix. The composition may also comprise a delivery matrix having at least 15% by weight of crude protein and a plurality of water-soluble film pieces dispersed throughout the delivery matrix. The plurality of water-soluble film pieces encompass an active agent therein, wherein the active agent is rapidly released from the composition upon contact with saliva from the pet. At least a portion of the released active agents may be oromucosally absorbed by the pet. | 2016-06-09 |
20160158148 | METHOD FOR TREATING A PERIODONTAL DISEASE - A method for treating a periodontal disease affecting a periodontal pocket of a patient. The method comprises inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, comprising a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent. | 2016-06-09 |
20160158149 | Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them - A pharmaceutical composition suitable for use in a dry powder inhaler comprising 70 mass %-99.5 mass % of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0.1 mass %-12.5 mass % of salmeterol xinafoate and 0.4 mass %-17.5 mass % of fluticasone propionate. | 2016-06-09 |
20160158150 | Manufacture of Pharmaceutical Compositions - The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process. | 2016-06-09 |
20160158151 | ON DEMAND VESICLE FORMATION FROM VESICLE PRECURSORS SUITABLE FOR LONG-TERM STORAGE - Disclosed is a water-in-oil-in-water (W/O/W) double emulsion including a first water phase, an oil phase and a second water phase, wherein the W/O/W double emulsion is disposed in an isotonic solution, and related methods of making the W/O/W double emulsion. Also disclosed is a method of making an artificial antigen presenting cell including: providing a W/O/W double emulsion that is stored in an isotonic solution, wherein the W/O/W double emulsion includes a peptide associated with a Major Histocompatibility (pMHC) complex or a glycolipid antigen associated with a CD1d molecule, and a costimulatory molecule; and transferring the W/O/W double emulsion to an electrolyte solution, wherein the double emulsion undergoes a morphological transformation to become the artificial antigen presenting cell. Also disclosed is a method of drug delivery including administering to a subject a unilamellar vesicle containing the drug. Other methods relate to storing a protein including making a water-in-oil-in-water (W/O/W) double emulsion, wherein the W/O/W double emulsion includes the protein, and wherein the W/O/W double emulsion is configured to be stably stored. | 2016-06-09 |
20160158152 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIMINUTION OF BONE TISSUE - A method for prevention and/or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV/TV%) by | 2016-06-09 |
20160158153 | MULTICOMPARTMENTAL LIPID NANOPARTICLES - The present invention relates to novel multicompartmental lipid nanoparticles (or cellisomes) with excellent stability comprising a first lipophilic compartment (lipid matrix) partly anchored to a second hydrophilic compartment delimited by a phospholipid bilayer (bilayer), as well as the method for preparing same and the use thereof as a vector for administering a wide variety of molecules of interest. | 2016-06-09 |
20160158154 | PROTEIN VESICLES AND METHODS OF MAKING AND USING THEREOF - Hollow, protein vesicles are provided. The protein vesicles can be loaded with desired cargo to be delivered to a subject, for example a human. One embodiment provides a protein vesicle made of a protein membrane surrounding a hollow core. The protein membrane includes a first and a second modular protein amphiphile. The first modular protein amphiphile includes a hydrophobic block and a first hydrophilic protein binding block. The second modular protein amphiphile includes a variable polypeptide block and a second hydrophilic protein binding block that binds to the first hydrophilic protein binding block. The first and second protein amphiphiles self-assemble to form the hollow, protein vesicle. | 2016-06-09 |
20160158155 | MAGNETIC NANOPARTICLES USEFUL FOR MAGNETIC SENSOR DETECTION ESPECIALLY IN BIOSENSOR APPLICATIONS - Disclosed is process for preparing magnetic nanoparticles (MNPs) that results in very sensitive MNPs that can be used in a variety of diagnostic and analytical methods. The MNPs exhibit superparamagnetism and find special use in giant magnetoresistance sensors (GMRS). The MNPs are created by a process that permits one to tune the size of nanoparticles to a range of from 10 to 20 nanometers with a very small particle size distribution of +/−2 nanometers or less. The MNPs can be tagged with a variety of markers and thus find use in many analytical assays, cell sorting techniques, imaging methods, drug delivery methods and cancer treatments. The inventive MNPs can be detected in magnetic file strengths of 2000 Oe or less. | 2016-06-09 |
20160158156 | HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS - Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution. | 2016-06-09 |
20160158157 | ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION - The present invention relates to an oral pharmaceutical fixed dose composition for use in the treatment of | 2016-06-09 |
20160158158 | Encased Tamper Resistant Controlled Release Dosage Forms - In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C. | 2016-06-09 |
20160158159 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 2016-06-09 |
20160158160 | NANOFIBROUS MATERIALS AS DRUG, PROTEIN, OR GENETIC RELEASE VEHICLES - The present invention is a bioactive, nanofibrous material construct which is manufactured using a unique electrospinning perfusion methodology. One embodiment provides a nanofibrous biocomposite material formed as a discrete textile fabric from a prepared liquid admixture of (i) a non-biodegradable durable synthetic polymer; (ii) a biologically active agent; and (iii) a liquid organic carrier. These biologically-active agents are chemical compounds which retain their recognized biological activity both before and after becoming non-permanently bound to the formed textile material; and will become subsequently released in-situ as discrete freely mobile agents front the fabric upon uptake of water from the ambient environment. | 2016-06-09 |
20160158161 | PLASTER CONTAINING FENTANYL - A process for producing an adhesive matrix for a transdermal therapeutic system comprising a cover layer, the adhesive matrix, and a removable protective layer. The process includes providing a solution comprising polybutyl titanate dissolved in heptane:ethyl alcohol, providing an acrylate copolymer consisting of units of 2-ethylhexyl acrylate, methacrylate and 2-hydroxyethyl acrylate, adding the solution to the acrylate copolymer to obtain a mixture, and adding fentanyl as an active ingredient to the mixture to obtain the adhesive matrix. | 2016-06-09 |
20160158162 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES - The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents. | 2016-06-09 |
20160158163 | Method For Treating Gefitinib-Resistant Non-Small-Cell Lung Cancer - The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analogue, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analogue to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase. | 2016-06-09 |
20160158164 | PTEROSTILBENE (PTER) FOR USE IN THE PREVENTION AND/OR TREATMENT OF SKIN DISEASES, DAMAGES OR INJURIES - The present invention refers to the use of PTER, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, for the manufacture of pharmaceutical compositions for preventing and/or treating skin diseases, damages or injuries. Those methods of prevention and/or treatment comprise the administration of an effective amount of a composition comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, to the subject. The present invention also refers to the compositions, per se, comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable slat thereof, characterized by being formulated in the form of liposomes, and to the method for preparing said liposome formulations. | 2016-06-09 |
20160158165 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders - The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout. | 2016-06-09 |
20160158166 | METHODS OF REDUCING BRAIN CELL APOPTOSIS - A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and/or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event. | 2016-06-09 |
20160158167 | THERAPEUTIC AGENTS FOR USE IN THE PROPYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS - (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyllamine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia. | 2016-06-09 |
20160158168 | METHODS FOR THE BIOSYNTHESIS OF TAURINE OR HYPOTAURINE IN CELLS - The present invention describes an approach to increase taurine or hypotaurine production in prokaryotes. More particularly, the invention relates to genetic transformation of organisms with genes that encode proteins that catalyze the conversion of cysteine to taurine, methionine to taurine, cysteamine to taurine, or alanine to taurine. The invention describes methods for the use of polynucleotides that encode cysteine dioxygenase (CDO) and sulfinoalanine decarboxylase (SAD) polypeptides in prokaryotes to increase taurine, hypotaurine or taurine precursor production. The preferred embodiment of the invention is in plants but other organisms may be used. Increased taurine production in prokaryotes could be used as nutraceutical, pharmaceutical, or therapeutic compounds or as a supplement in animal feed. | 2016-06-09 |
20160158169 | Antimicrobial Compositions with Cysteamine - The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections. | 2016-06-09 |
20160158170 | Delayed Release Cysteamine Bead Formulation, And Methods Of Making And Using Same - An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed. | 2016-06-09 |
20160158171 | METHOD FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 2016-06-09 |
20160158172 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME - Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein. | 2016-06-09 |
20160158173 | METHODS FOR TREATING BRAIN INJURY - The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). | 2016-06-09 |
20160158174 | Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients - Functional food ingredients for delivery to the gastrointestinal tract are delivered. Food products, nutraceuticals, and pharmaceuticals comprising the functional food ingredients, as well as methods for making the functional food ingredients, are also provided. The functional food ingredients may positively influence glucose metabolism and weight management. Generally, the ingredients include metabolites physically entrapped in a fermentation precursor, which is then encapsulated in an enteric coating for release in the large intestine of a human subject. In one approach, the ingredients include a polysaccharide matrix, short chain fatty acids physically entrapped in the polysaccharide matrix, and an enteric coating that encapsulates the combination of short chain fatty acids and polysaccharide matrix. | 2016-06-09 |
20160158175 | CITRATE RESORPTION OF BONE AS A TREATMENT FOR SPINAL STENOSIS - Spinal stenosis is a common debilitating illness that produces symptoms of neurogenic claudication, radiculopathy and weakness. Present therapies include administration of analgesics, epidural injections of local anesthetic with corticosteroids and decompression laminectomy. In vitro, citrate ion can resorb vertebral cortical bone by chelating calcium without destruction of the ligamentum flavum or dura mater. This non-enzymatic spontaneous chemical reaction occurs at neutral pH, 37° C. and in an isotonic solution and in vitro produces an average cortical bone weight loss of 17% after 168 hours. In this invention epidural infusion of citrate in the form of an isotonic solution of sodium citrate/citric acid buffer at neutral pH will resorb a significant amount of vertebral bone such that the symptoms of spinal stenosis are ameliorated. | 2016-06-09 |
20160158177 | NUTRITIONAL COMPOSITION FOR IMPROVING BRAIN FUNCTION IN PHENYLKETONURIA - The present invention relates to food compositions comprising nutritional composition for use in the treatment or nutritional management of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or hyperphenylalaninemia. The composition comprises a specific protein source, long chain polyunsaturated fatty acids and at least one of uridine or cytidine. | 2016-06-09 |
20160158178 | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction. | 2016-06-09 |
20160158179 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a | 2016-06-09 |
20160158180 | Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state. | 2016-06-09 |
20160158181 | Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments - Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state. | 2016-06-09 |
20160158182 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE DONOR - The present invention relates to compositions comprising a 4-nitrooxybutan-1-ol alkyl ester as nitric oxide donor. More specifically, the invention relates to compositions comprising 4-nitrooxybutan-1-ol alkyl ester as a nitric oxide donor and an ophthalmic drug, useful in controlling elevated intraocular pressure associated with glaucoma or ocular hypertension associated with other diseases or conditions. The invention is also directed to methods of controlling intraocular pressure utilizing said compositions. | 2016-06-09 |
20160158183 | COMPOSITIONS AND METHODS COMPRISING MEDIUM CHAIN TRIGLYCERIDES FOR TREATMENT OF EPILEPSY - The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a dietary regime suitable for enhancing the effect of an anti-epileptic drug (AED) in an animal can comprise a food composition comprising a medium chain triglyceride (MCT) and the AED, wherein the MCT is present in the food composition in an effective amount for enhancing the effect of the AED when the food composition and the AED are administered to the animal. | 2016-06-09 |
20160158184 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID - A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ω3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine. | 2016-06-09 |
20160158185 | SARMS AND METHOD OF USE THEREOF - This invention is directed to substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy. | 2016-06-09 |
20160158186 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR - Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed. These methods employ a hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, or a derivative or analog of diacetyldianhydrogalactitol. The compositions can include such hexitol derivatives. | 2016-06-09 |
20160158187 | TIGLIEN-3-ONE DERIVATIVES - The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment. | 2016-06-09 |
20160158188 | NOVEL USE FOR PAI-1 INHIBITOR - Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent. | 2016-06-09 |
20160158189 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES - The present invention relates to a combined preparation for simultaneous, separate or sequential use comprising at least one flavagline or a pharmaceutically acceptable salt thereof; and/or at least one 5-hydroxy-flavone or a pharmaceutically acceptable salt thereof; and at least one agent activating the intrinsic pathway of apoptosis for use in the treatment of cancer. The N present invention further relates to a medicament comprising the combined preparation of the present invention, as well as to a kit comprising the combined preparation or a medicament according to the present invention and a means for administering at least one of its components. Moreover, the present invention relates to a method of inhibiting a cancer cell, comprising contacting said cancer cell with the combined preparation of the present invention, and thereby inhibiting said cancer cell. | 2016-06-09 |
20160158190 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation - This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject. | 2016-06-09 |
20160158191 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders - The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout. | 2016-06-09 |
20160158192 | Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders - The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout. | 2016-06-09 |
20160158193 | ADJUVANTS IN ANTI-CANCER CHEMOTHERAPY - The present invention provides a 1,2,4-trioxane or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof for use as an adjuvant for a tyrosine kinase inhibitor to enhance the activity of said tyrosine kinase inhibitor in a method for the treatment of a patient suffering from cancer, a pharmaceutical composition comprising a tyrosine kinase inhibitor as an active ingredient and said 1,2,4-trioxane adjuvant or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof in an amount sufficient to enhance the activity of the tyrosine kinase inhibitor, preferably for use in a method for the treatment of cancer. | 2016-06-09 |
20160158194 | Methods and Treatments for the Learning and Memory Deficits Associated with Noonan Syndrome - Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome. | 2016-06-09 |
20160158195 | REDUCTION OF EPILEPTIC SEIZURES - Compositions for use in a method of treatment, particularly for use in a method of treatment of epilepsy or an epilepsy-related disorder, are provided. Uses of the compositions are also described, along with methods for employing the compositions. The described compositions reduce the frequency and severity of epileptic seizures. | 2016-06-09 |
20160158196 | A MODIFIED-RELEASE ORAL PHARMACEUTICAL FORMULATION CONTAINING GLICLAZIDE - Sustained-release Gliclazide tablets devoid of calcium phosphate dibasic, and containing only soluble excipients. The mixing of two high viscosity HPMC with a low viscosity one allows to obtain releases similar to those of the reference products on the market, and it shows also a certain pH dependence. | 2016-06-09 |
20160158197 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders - The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety. | 2016-06-09 |
20160158198 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA - The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called “beta blockers”, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof. | 2016-06-09 |
20160158199 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS - Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist. | 2016-06-09 |
20160158200 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. | 2016-06-09 |
20160158201 | CHEMICAL COMPOUNDS - Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. | 2016-06-09 |
20160158202 | Low Dose Pharmaceutical Composition - This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity. This invention also provides a process for preparing the low dose pharmaceutical composition, the process comprising: dissolving or adsorbing or blending deferasirox and at least one excipient to produce a dispersion of deferasirox; and processing the dispersion to produce a desired dosage form. | 2016-06-09 |
20160158203 | METHODS OF TREATMENT WITH BIOAVAILABLE COMPOSITIONS OF METAXALONE COMPRISING NONVOLATILE LIQUIDS - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 2016-06-09 |
20160158204 | PHARMACOLOGICAL STIMULATION TO FACILITATE AND RESTORE STANDING AND WALKING FUNCTIONS IN SPINAL CORD MOTOR DISORDERS - The invention relates to the selective targeting of specific α2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the α2c receptor subtype using an α2c specific agonist or by blocking the α2a receptor subtype using α2a antagonists. A combination of an α2c agonist and an α2a antagonist is also provided for a synergistic effect. Alternatively, a large α2 agonist can be used in combination with an α2a antagonist to achieve specific stimulation of the α2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention. A robotic interface and epidural electric stimulation can also be used in combination with the compositions of the invention for restoring voluntary control of locomotion. | 2016-06-09 |
20160158205 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS - Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof. | 2016-06-09 |
20160158206 | Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism - An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation. | 2016-06-09 |
20160158207 | THERAPEUTIC COMPOUNDS AND USES THEREOF - The present invention relates to compounds of formula (I) or formula (II): | 2016-06-09 |
20160158208 | METHODS OF USE OF CYCLOPAMINE ANALOGS - The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: | 2016-06-09 |
20160158209 | Compounds for Treatment of Alzheimer's Disease - The invention is directed to the use of a compound of formula I, as defined herein, to a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing a compound of formula I, and to a combination of a compound of formula I with a pharmacologically effective cholinesterase inhibitor to treat a mammal, including a human, for a disorder or condition selected from the list including Alzheimer's disease, Huntington's disease, Parkinson's disease, non-Alzheimer's dementias and ALS. | 2016-06-09 |
20160158210 | CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS - The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide. | 2016-06-09 |
20160158211 | Dosage and Use of an A2A Antagonist - The present invention relates to specific dosages of an A | 2016-06-09 |
20160158212 | EXTENDED RELEASE AQUEOUS SUSPENSION OF METHYLPHENIDATE OR SALTS THEREOF - An extended release aqueous suspension composition of methylphenidate or salts thereof, is provided. The extended release aqueous suspension of methylphenidate or salts has pH below 3.5 and exhibit excellent storage stability when tested for impurity and potency of methylphenidate. The suspension also comprises immediate release and sustained release components of methylphenidate or salts thereof. Following administration of a single dose of the extended release aqueous suspension of methylphenidate, a therapeutically effective amount of methylphenidate is reached in less than an hour, provides release profile of at least 12 hours and its vivo release is characterized by one single main plasma concentration peak. | 2016-06-09 |
20160158213 | USE OF FLECAINIDE AS AN ANTI-CONNEXIN AGENT AND METHOD FOR POTENTIATING THE EFFECTS OF A PSYCHOTROPIC DRUG - The present invention relates to the use of flecainide as an anti-connexin agent. This anti-connexin agent is advantageously used to potentiate the therapeutic effect of various psychotropic drugs. More specifically, the invention provides a combination product containing flecainide and modafinil. | 2016-06-09 |
20160158214 | HEPATITIS B ANTIVIRAL AGENTS - Provided herein are compounds useful for the treatment of HBV infection in man. | 2016-06-09 |